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Emphysema as a Risk Factor for the Outcome of Surgical 
Resection of Lung Cancer
It is unclear whether emphysema, regardless of airflow limitation, is a predictive factor 
associated with survival after lung cancer resection. Therefore, we investigated whether 
emphysema was a risk factor associated with the outcome after resection for lung cancer. 
This study enrolled 237 patients with non small cell lung cancer with stage I or II who had 
surgical removal. Patient outcome was analyzed based on emphysema.  Emphysema was 
found in 43.4% of all patients. Patients with emphysema were predominantly men and 
smokers, and had a lower body mass index than the patients without emphysema. The 
patients without emphysema (n=133) survived longer (mean 51.2±3.0 vs. 40.6±3.1 months, 
P=0.042) than those with emphysema (n=104). The univariate analysis showed a younger 
age, higher FEV1/FVC, higher body mass index, cancer stage I, and a lower emphysema score 
were significant predictors of better survival. The multivariate analysis revealed a younger 
age, higher body mass index, and cancer stage I were independent parameters associated 
with better survival, however, emphysema was not. This study suggests that unfavorable 
outcomes after surgical resection of lung cancer should not be attributed to emphysema 
itself.
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Oncology & Hematology
INTRODUCTION
 
Lung cancer is the leading cause of death in cancer related mor-
tality (1, 2). Complete surgical resection at an early stage is the 
only possible curative option for the treatment of lung cancer. 
Age, smoking, stage, and underlying lung function have been 
reported to be associated with the prognosis of patients after 
resection for lung cancer (3-5). However, even though lung can-
cer might be detected at an early stage, co-morbidities combined 
with the lung cancer often prevent patients from undergoing a 
surgical resection. Chronic obstructive pulmonary disease (COPD) 
is often diagnosed in patients with lung cancer, because COPD 
and lung cancer are mainly caused by smoking. COPD tradition-
ally includes chronic bronchitis characterized by airflow limita-
tion and emphysema with alveolar wall destruction. Emphyse-
ma is often detected even with no airflow limitation when chest 
tomography is performed for evaluations of lung cancer.
  In some patients with lung cancer, there is a concern that the 
operative morbidity and mortality may be affected by the pres-
ence of emphysema; this may cause surgeons to be reluctant to 
subject patients to surgical treatment. The safety of surgical re-
sections in patients with emphysema has not been resolved and 
the impact of emphysema on surgical outcome has not been 
clearly defined in patients with early lung cancer.    
  Therefore, the goal of this study was to investigate whether 
emphysema is a risk factor associated with the outcome of sur-
gical resection in patients with early lung cancer.
MATERIALS AND METHODS
Subjects 
This study enrolled 237 consecutive patients with stage I or II 
non-small cell lung cancer (NSCLC) that underwent surgical 
resection from March 2003 to July 2007 at Ajou Medical Center 
(a university affiliated 1000-bed sized tertiary referral center in 
Suwon, Korea). The decision to perform a surgical resection for 
the patients with lung cancer was made through discussion in 
the joint conference where pulmonologist, thoracic surgeon, 
oncologist, radiation oncologist, and radiologist participated. 
Age, FEV1, performance, and staging were the main factors in Lee SA, et al.  •  Emphysema in the Resection of Lung Cancer
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the decision regarding surgical resection.
  The data were collected and analyzed retrospectively. All pa-
tients were followed in the outpatient clinic at three to six month 
intervals during the first three years after surgery. For the patients 
who are lost during follow up, telephone interview had us get the 
information on the patient’s survival.
  This study was approved by the Institutional Review Board of 
Ajou University Hospital (Approval number: AJIRB-CRO-08169). 
Diagnostic criteria
The diagnosis of lung cancer was made using various methods, 
for example, sputum cytology, thoracentesis, fine needle aspi-
ration, or bronchoscopy, as dictated by the patient’s presenta-
tion. Pathologists interpreted the cytology or histology of tissue 
biopsy. The lung cancer was staged using a widely used classifi-
cation system (6, 7) and the staging procedure included a clini-
cal examination, standard chest radiography, computed tomog-
raphy (CT) of the chest, abdomen, and brain, bronchoscopy, 
abdominal ultrasonography, bone scanning, and positron emis-
sion tomography (PET). For precise staging, only patients in 
whom pathologic staging was possible due to resection surgery 
were selected.
  The diagnosis of COPD was determined by clinical criteria 
and previously documented airflow limitation (FEV1 <80% of 
the predicted value in combination with an FEV1/FVC <70% that 
is not fully reversible (8, 9). The severity of COPD was dictated 
by GOLD criteria (9). Spirometry was performed according to 
American thoracic society guidelines within 1 month before re-
section was performed (10).
  Two radiologists who were blinded to the clinical informations 
determined the presence of emphysema and emphysema score 
by reviewing the thin-section CT scans.
CT scanning
All examinations were performed at our medical center using a 
16-detector-row CT scanner. The CT examinations included pre 
and post-contrast scanning. The scanning parameters were 120 
kVp and 70-200 mA. In all individuals, the scanning was per-
formed during breath-holding at end inspiration. The thin-sec-
tion CT scans were obtained with reconstruction thickness 1– 
1.2 mm using a high-frequency algorithm. When post-contrast 
scans were performed, a single phase contrast enhancement 
study was obtained after intravenous injection of nonionic con-
trast media (2.5 mL/sec, total of 100 mL of Iomeprol [Iomeron 
300]; Bracco, Milan, Italy) using a power injector with a fixed 
delay time of 45 sec. The image data were reconstructed using a 
lung filter kernel at a slice thickness setting of 4 mm, at a 4-mm 
reconstruction increment.
CT scoring
A total of five levels (6 and 3 cm above carina; carina; and 3 and 
6 cm below carina) were evaluated using thin-section scanning 
to score the severity and extent of emphysema; two radiologists 
assessed the findings using direct observational methods (11-
13). When disagreements occurred, a consensus was achieved. 
Severity was graded according to a 4 point scale as follows: 0, 
no emphysema; 1, all low-attenuation areas smaller than 5 mm 
in diameter; 2, all circumscribed low-attenuation areas larger 
than 5 mm in diameter in addition to those circumscribed areas 
smaller than 5 mm in diameter; 3, diffuse low-attenuation areas 
without intervening healthy lung or large, confluent low-atten-
uation areas. The extent of emphysema was also graded using a 
4 point scale as follows: 1, less than 25% lung involvement; 2, 
25-50% lung involvement; 3, 50-75% lung involvement; 4, more 
than 75% lung involvement. For each of the 10 lung sections, 
the score for the respective section was obtained by multiplying 
the severity of emphysema by the extent of emphysema score. 
The total score, ranging from 0 to 120, was obtained by adding 
each score for the 10 lung sections. 
  Finally, the patients with emphysema were grouped into four 
subgroups by the cumulative frequency scores: mild emphyse-
ma (Grade 1; emphysema scoring 1-10), moderate emphysema 
(Grade 2; 11-16), severe emphysema (Grade 3; 17-31), and very 
severe emphysema (Grade 3; 32-101).
Statistical analysis
SPSS version 12 (SPSS Inc., Chicago, IL, USA) was used for the 
analysis. All values are given as means±standard deviation, ex-
cept for the survival period in which the mean±standard error 
was used. The values did not fit a standard distribution, so non-
parametric analysis was performed. Survival curves were plot-
ted using the Kaplan–Meier method, and the significance of 
differences between groups was analyzed using the log-ranks 
test. A Cox proportional hazards model multivariate analysis 
was used to evaluate factors contributing to survival. A value of 
P<0.05 was considered statistically significant.
RESULTS
Baseline clinical and demographic features of the patients
The subjects were 237 consecutive patients (189 males and 48 
females, mean age: 63.0±10.6 yr) that had NSCLC surgically re-
moved. Emphysema was found in 43.4% of all patients with lung 
cancer. After surgical resection of the lung cancer, 67.1% of all 
patients were confirmed to have stage I disease. 
Patient characteristics according to the presence or 
absence of emphysema 
The emphysema patients were older and had a lower body mass 
index (BMI) compared to the patients without emphysema. 
Smokers were predominant in the emphysema group (90.3% 
vs. 67.4%; P<0.001). Accordingly, squamous cell carcinoma, Lee SA, et al.  •  Emphysema in the Resection of Lung Cancer
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which occurs mostly in smokers, was more frequent in patients 
with emphysema; adenocarcinoma was more common in the 
patients without emphysema (Table 1).  
  Airway obstruction represented by the FEV1 (80.9±20.7% vs. 
88.8±20.8%; P=0.004) and FEV1/FVC (69.5±13.27% vs. 76.1±9.8% 
P<0.001) was worse in the patients with emphysema than in 
those without emphysema. However, there was no significant 
difference in the blood gas findings between the two groups 
(Table 1).
Postoperative complications and mortality 
For the patients with emphysema, the hospital stay tended to 
be longer compared to the patients without emphysema. How-
ever, there was no significant difference in the duration of inten-
sive care unit (ICU) stay or chest tube placement after surgical 
resection (Table 2).
  The mortality after surgical resection at 30 days was 2.9% in 
all patients with lung cancer, and the mortality at 90 days was 
7.6%. However, there was no significant difference in the mor-
tality rate at 1 month or 3 months based on the presence of em-
physema. In addition, the complication rate was not different 
between the two groups. The most common postoperative com-
plication was pneumonia, which occurred in 12.5% of the pa-
tients with emphysema and in 9.0% of the patients without em-
physema (Table 2).
Survival of NSCLC patients depending on emphysema
Using the log rank test, the survival curves were compared be-
tween patients with and without emphysema. In all patients, the 
patients without emphysema (n=133, mean: 51.2±3.0 months) 
survived longer than those with emphysema (n=104, mean: 
40.6±3.1 months, P=0.042) (Fig. 1). Likewise, for stage I lung 
Table 1. Patient characteristics according to the presence or absence of emphysema
Variables Emphysema No-emphysema P value
Total number 104 133
Age 66.5±8.1   60.4±11.5 <0.001
Male 91.3% (95/104) 70.7% (94/133) <0.001
Smoker (%) 90.3% (93/103) 67.4% (89/132) <0.001
BMI (kg/m
2) 21.9±3.4 23.7±2.7 <0.001
Stage I (%) 59.6% (62/104)   72.9% (97/133) 0.037
Pulmonary function
   FVC (%)
   FEV1 (%)
   FEV1/FVC (%)
  89.5±19.3 
  80.9±20.7
  69.5±13.2
  90.5±17.5
  88.8±20.8
76.1±9.8 
0.663
0.004
<0.001
Blood Gas  n=58 n=82
   PaCO2 mmHg 
   PaO2 mmHg 
37.5±6.3 
  91.0±23.9 
37.2±4.5
  95.6±18.6
0.801
0.201
Cell type 0.033
   Sqaumous
   Adeno
   Large 
   BAC 
60.6% (63/104)
27.9% (29/104) 
4.8% (5/104) 
0% (0)
 42.9% ( 57/133)
42.9% (57/133)
4.5% (6/133)
3.0% (4/133)
Operation for lung cancer 0.948
   Lobectomy
   Sleeve resection 
   Wedge resection
   Bi-lobectomy
   Pneumonectomy
72 (69.2%)
13 (12.5%)
1 (1.0%)
7 (6.7%)
11 (10.6%)
94 (70.7%)
18 (13.5%)
  2 (1.5%)
  6 (4.5%)
13 (9.8%)
NSCLC, non-small cell lung cancer; BMI, body mass index; BAC, bronchioloalveolar 
carcinoma.
Table 2. Postoperative complication and mortality 
Variables Emphysema No-emphysema P value
Total number 104 133
Length of hospital stay (day) 17.0±20.5 13.1±9.5 0.056
Length of ICU stay (day) 3.7±6.8   3.0±6.5 0.438
Chest tube duration(day)  9.9±8.4   8.2±7.9 0.106
30 day Mortality (%)        2.9% (3/104)         3.0% (4/133) 1.000
90 day Mortality (%)        8.7% (9/104)        6.9% (9/133) 0.610
Complication after surgery 19.2% (20) 14.3% (19) 0.308
   Pneumonia
   Sepsis
   ARDS 
   Myocardial infarction
   Bleeding
   Pneumothorax
   Prolonged air leak
   Arrhythmia 
   Renal failure
12.5% (13)
0.0% (0)
2.9% (3)
1.0% (1)
1.9% (2)
1.9% (2)
4.8% (5)
1.9% (2)
1.9% (2)
  9.0% (12)
0.8% (1)
1.5% (2)
0.8% (1)
1.5% (2)
2.3% (3)
      6% (0.8)
2.3% (3)
1.5% (2)
0.387
1.000
0.656
1.000
1.000
1.000
1.000
1.000
1.000
NSCLC, non-small cell lung cancer; ARDS, acute respiratory distress syndrome.
Fig. 1. Kaplan-Meier curves for Survival of total Patients depending on the presence of 
emphysema (    emphysema (n=104), mean survival, 40.6±3.1 months;    non em-
physema (n=133) mean survival, 51.2±3.0 months, P=0.042).
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Fig. 2. Kaplan-Meier curves for survival of NSCLC patients with stage I depending on 
the presence of emphysema (     emphysema (n=62), mean survival, 44.0±3.9 months;
    non emphysema (n=97), mean survival, 57.9±3.1 months, P=0.036).Lee SA, et al.  •  Emphysema in the Resection of Lung Cancer
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cancer, patients without emphysema survived longer (n=97, 
mean: 57.9±3.1 months) than those with emphysema (n=62, 
mean: 44.0±3.9 months, P=0.036) (Fig. 2). In addition, in select-
ed patients with stage I lung cancer and a normal FEV1 (FEV1 
≥80%), patients without emphysema survived slightly longer 
(n=68, mean: 55.4±2.9 months) than those with emphysema 
(n=32, mean: 46.6±5.3 months, P=0.076). 
  When survival was analyzed by grouping patients based on a 
25% cumulative frequency of the emphysema scoring, only the 
patients with very severe emphysema survived for a far shorter 
period than the other three subgroups (Fig. 3). The Cox regres-
sion analysis was used to analyze the association of emphyse-
ma and other factors to patient survival. According to the uni-
variate Cox model, a younger age, higher FEV1/FVC, higher BMI, 
cancer stage, and lower emphysema score were significantly 
associated with a better survival (Table 3). The multivariate anal-
ysis of all patients revealed that a younger age, higher BMI, and 
stage I disease were independent parameters associated with a 
better survival; however, emphysema per se and the emphyse-
ma grade were not independent factors associated with survival 
(Table 4).
DISCUSSION
The results of our study demonstrated that in patients with early 
resected NSCLC (stage I and II), emphysema was not an inde-
pendent parameter associated with survival after the resection 
of lung cancer. The findings showed that patients with emphy-
sema had longer hospital stay and shorter survival on the uni-
variate analysis. Patients without emphysema survived longer 
than those with emphysema after surgical resection of lung can-
cer, even in selected patients with cancer stage I. After lung can-
cer resection, the survival time of a subgroup with very severe 
emphysema was shorter than in the other three subgroups (no, 
mild, moderate, and severe emphysemas), when survival was 
analyzed by grouping patients based on a 25% cumulative fre-
quency of the emphysema scoring. 
  However, the results of the multivariate analysis showed that 
age, cancer stage, and BMI were independent factors associat-
ed with survival after the resection of lung cancer, whereas em-
physema per se was not a significant factor nor was the emphy-
sema scoring. This discrepancy between the univariate and mul-
tivariate analysis might be attributed to the demographic data 
showing older smokers and diminished pulmonary function in 
the patients with emphysema. These confounding factors might 
have affected the prognosis after lung cancer resection and should 
be adjusted by the multivariate analysis, as shown in our data. 
  Patients with NSCLC have a higher prevalence rate of co-mor-
bidity associated with age and smoking. This co-morbidity can 
have a significant impact on survival after surgical resection of 
patients with early NSCLC (14, 15). Therefore decisions to pro-
ceed with surgery in such patients should be made on a case by 
case basis weighing the clinical benefits and risks based on the 
Table 3. Univariate analysis of the prognostic factors in NSCLC patients using Cox 
proportional hazards model
Variables No. Hazard ratio 95% CI P value
Age (yr) 237 1.042 1.017-1.068   0.001
Male sex 237 2.153 1.036-4.476   0.040
Smoker vs. non-smoker  235 2.252 1.082-4.688   0.030
FVC (%) 235 1.000 0.989-1.011   0.978
FEV1 (%) 235 0.994 0.984-1.003   0.201
FEV1/FVC (%) 235 0.976 0.960-0.994   0.008
BMI (kg/m
2) 235 0.844 0.784-0.909 <0.001
Stage II vs. stage I 237 2.175 1.396-3.388   0.001
Emphysema score  213 1.016 1.006-1.027   0.003
Emphysema grade 213 1.269 1.086-1.484   0.003
Presence of emphysema 222 1.257 1.007-1.569   0.043
BMI, body mass index; NSCLC, non-small cell lung cancer.
Table 4. Multivariate analysis of the prognostic factors in NSCLC patients using Cox 
proportional hazards model
(1) Multivariate analysis in total patients with NSCLC 
Variables No. Hazard ratio 95% CI P value
Age (yr) 219 1.032 1.005-1.061   0.021
Gender (male vs. female)    219 2.226 0.662-7.486   0.220
Smoker vs. non-smoker  219 1.312 0.732-2.352   0.362
FEV1/FVC (%) 219 0.990 0.970-1.010   0.321
BMI (kg/m
2) 219 0.826 0.752-0.907 <0.001
Staging (II vs. I) 219 2.270 1.406-3.666   0.001
Emphysema 219 1.261 0.748-2.125   0.384
(2) Multivariate analysis in total patients with NSCLC using emphysema grade
Variables No. Hazard ratio 95% CI P value
Age (yr) 209 1.035 1.006-1.065 0.019
Gender (male vs. female)    209 2.226 0.671-7.386 0.191
Smoker vs. non-smoker  209 1.203 0.677-2.138 0.529
FEV1/ FVC (%) 209 0.989 0.969-1.010 0.296
BMI (kg/m
2) 209 0.872 0.798-0.954 0.003
Staging (II vs. I) 209 1.957 1.214-3.155 0.006
Emphysema grade 209 1.004 0.833-1.209 0.969
BMI, body mass index; CI, confidence interval; NSCLC, non-small cell lung cancer.
Fig. 3. Survival of NSCLC Patients based on the degree of emphysema (Mean survival 
period of each group; Emp 0 (Grade 0, n=133), 51.2±3.0 months; Emp 1 (Grade 1, 
n=19), 41.7±7.6 months; Emp 2 (Grade 2, n=21), 41.1±5.7 months; Emp 3 (Grade 
3, n=20), 44.2±6.8 months; Emp 4 (Grade 4, n=20), 26.3±7.1, P=0.07).
Emp, emphysema. 
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significant associated outcome factors reported in this study. 
However, the findings of this study should reassure clinicians 
with regard to surgical therapy in early NSCLC patients that have 
emphysema.
  When we confront the patients with severe emphysema who 
are about to undergo surgical resection, authors’ opinion is that 
clinicians should be alerted more to risk factors including age, 
cancer stage, BMI, and pulmonary function test which may pos-
sibly have an influence on the prognosis after surgery than em-
physema itself because severe emphysema can be accompanied 
with many co-morbidities. 
  NSCLC patients up to stage II, determined by surgical resec-
tion, were enrolled in our study. These patients were chosen 
because of the conflicting opinions on the necessity of surgery 
in the patients with stage IIIa lung cancer (16, 17). 
  Airway obstruction represented by the FEV1, the most impor-
tant factor for patient prognosis after surgery, was not a crucial 
factor in this study. This finding is likely explained by the fact that 
patients with severe airway obstruction were not considered can-
didates for surgery. 
  BMI, has been shown to be an independent factor in the prog-
nosis of patients with COPD; therefore nutritional care seems to 
be important for these patients (18, 19). The results of this study 
showed that a lower BMI had a significant impact on survival 
after surgical resection. Therefore, it is thought that BMI should 
be considered an additional risk factor for surgery in patients 
with lung cancer. 
  COPD traditionally includes chronic bronchitis characterized 
by airflow limitation and emphysema with alveolar wall destruc-
tion. Because emphysema is often present without airflow limi-
tation detected by pulmonary function testing, emphysema can 
go unnoticed unless a chest CT reveals lung parenchymal de-
struction. Therefore, emphysema might be more frequently found 
in patients with lung cancer because thorough evaluations in-
cluding chest CT are usually performed. Emphysema can even 
be an independent risk factor for the development of lung can-
cer (20). Our data showed that 43.4% of patients with lung cancer 
had emphysema. One retrospective study reported that twelve 
percent of all cancer patients had COPD at the time of the cancer 
diagnosis and COPD was associated with reduced survival in a 
variety of cancers including breast, prostate, and urinary blad-
der cancer in middle aged patients, and in colon, larynx, pros-
tate, and urinary bladder cancer in elderly patients (21). How-
ever, the impact of emphysema on the outcome of surgery for 
lung cancer continues to be debated. Ueda et al. reported that 
emphysema diagnosed by computed tomography was associ-
ated with a poor prognosis after surgical resection in patients 
with lung cancer (22). Their study is supported by theories sug-
gesting that emphysema may reflect an increased susceptibility 
to smoking related biological damage, which ultimately deter-
mines the aggressiveness of tumor cells (23). In addition, tumor 
progression may be enhanced in emphysematous lungs where 
metalloproteinases are abundant (24). However, conflicting opin-
ions have also existed. Patients with resectable lung cancer and 
emphysema may have a good long term survival after cancer 
resection because cancer resection provides a volume reduc-
tion effect (25). Patients with severe pulmonary dysfunction have 
had volume reduction surgery and pulmonary nodule resection, 
with favorable outcomes (26). 
  Previous studies have reported that postoperative ventilatory 
function, in patients with COPD, were well preserved after lobec-
tomy (27, 28). We did not have the information needed to report 
on a volume reduction effect in this study, as acknowledged in 
the limitations below.
  We acknowledge several limitations of this study. First, DLCO, 
which is associated with the degree of emphysema and progno-
sis after surgery, was not analyzed due to the retrospective de-
sign. Likewise, follow up by pulmonary function test was not 
conducted in a well-controlled manner, which might keep us 
from assessing postoperative condition exactly. Second, the eti-
ology of emphysema such as antitrypsin deficiency was not de-
termined because this disease is rare in Korean society. Third, a 
selection bias could have been present due to the fact that most 
patients resided in an area around Suwon city. Therefore, the 
patients in our study might not represent the Korean population. 
Fourth, decisions regarding surgery were determined by con-
sensus of the thoracic surgeon, pulmonologist and radiologist; 
only cases that had the stage confirmed pathologically were en-
rolled. However, the possibility of surgeon’s bias in selecting the 
candidate for resection of lung cancer cannot be ruled out and 
might have affected our data.
  In conclusion, the results of this study suggest that age, can-
cer stage, and BMI were independent factors associated with 
survival after resection of the lung cancer, whereas emphysema 
per se was not. Therefore, unfavorable outcomes after surgical 
resection should not be attributed to emphysema itself. 
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